to formulate CytoDyn's PRO 140 bulk drug substance through a fill-and-finish process for clinical-ready vials to advance two National Institutes of Health (NIH)-funded Phase IIb studies

In separate news, another Galapagos unit, Argenta, inked a deal with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to apply its respiratory drug discovery services to an undisclosed target within Boehringer's respiratory disease portfolio...In other news, BioInvent said the first patient has been treated in a Phase II study of BI-505 for smoldering multiple myeloma, or asymptomatic myeloma

Armgo Pharma Inc., of Tarrytown, N.Y., and the Muscular Dystrophy Association (MDA) said $1 million was awarded for preclinical work in support of an investigational new drug application for AMR201, an oral, small-molecule Rycal drug that has the potential to treat Duchenne's muscular dystrophy...In separate news, another Galapagos unit, Argenta, inked a deal with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to apply its respiratory drug discovery services to an undisclosed target within

As a result of the amendment, Takeda assumes full responsibility for Omontys and, should the big pharma opt to re-introduce the drug to the market, Affymax would be eligible to receive royalties and potential commercial milestone payments totaling up to $180 million

On a personal note, CEOs of big pharma companies would have to give 30 percent of their earnings – of $1 million or more – to the government, and the budget would limit the value of tax deductions and other tax benefits for other high-income earners who haven't entered the millionaire's club

Actinobac Biomed Inc., of New Brunswick, N.J., said it received a $202,000 Small Business Technology Transfer grant from the National Institutes of Health to study its drug candidate, Leukothera, in B-cell lymphomas...In other news, SCT closed its previously announced private placement for gross proceeds of C$3.2 million (US$3.1 million

Under the agreement, Pepscan will use its CLIPS platform and other protein mimicry technologies to help discover new antibodies...to purchase up to 1 million shares, or about 1.06 percent of the company's outstanding stock, at a price of $161.25 per share, marking a 4.46 percent discount to the Dec. 27 closing price...Reset Therapeutics, of Burlingame, Calif., said the National Institutes of Health awarded a five-year cooperative agreement to develop a drug for narcolepsy

The news came late Thursday, shortly after the company disclosed FDA approval of Cometriq in MTC...Isotechnika Pharma Inc., of Edmonton, Alberta, said a partial award has been issued in the company's ICC arbitration regarding its right to terminate the development, distribution and license agreement with Iljin Life Sciences Co...pSivida Corp., of Watertown, Mass., said the UK's National Institute for Health and Clinical Excellence (NICE) issued a final draft guidance indicating that Iluvien is not

Bavarian Nordic A/S, of Kvistgard, Denmark, said the Department of Homeland Security (DHS) Science and Technology Directorate and the National Institutes of Health (NIH) awarded the company two new contracts valued at up to $18.9 million for the development of recombinant modified vaccinia virus Ankara-based vaccines, building on the company's MVA-BN platform...In other news, Orexo said the FDA accepted for review its new drug application for Zubsolv, a sublingual formulation of buprenorphine and

rights to market Bethkis (tobramycin inhalation solution) for the management of cystic fibrosis patients with Pseudomonas aeruginosa...XenoPort licensed worldwide rights, excluding Asian territories, to Horizant to GSK in 2007 for $75 million in cash up front, $65 million in milestones leading up to the filing of a new drug application and an additional $210 million in other development and regulatory milestones, plus as much as $290 million in sales milestones...Immune Pharmaceuticals Ltd., of

The Drug Development Office at London-based Cancer Research UK is partnering with the UK's National Institute for Health Research and Imperial College London to conduct a Phase IIa trial of AZD4547, from AstraZeneca plc, of London, in combination with existing therapies, to treat postmenopausal women with metastatic breast cancer who are not responding to standard treatment...IL-17 mediated signaling is known to induce the expression of cytokines and other effectors in a variety of immunological

Bristol-Myers Squibb Co., of New York, said the National Institute of Health and Clinical Excellence decided to recommend Yervoy (ipilimumab), which is approved in Europe for treating advanced metastatic melanoma, within the final appraisal determination

Cellectis SA, of Paris, said its subsidiary, Cellectis bioresearch, was awarded a second contract to provide services to the National Institutes of Health and certain other government agencies...In other news, Cellectis said it signed two exclusive license agreements with Iowa State University granting the firm worldwide rights to inventions related to TAL effector-nucleases (TALENs) and monomeric TALENs

Cellular Dynamics International Inc., of Madison, Wis., said the National Institutes of Health Center for Regenerative Medicine (NIH-CRM) awarded the company a contract to provide human-induced pluripotent stem (iPS) cell lines and terminally differentiated tissue cells from normal or specified patient populations...In addition, they voted to approve a restated certificate of incorporation, a change of the company name from Nabi Biopharmaceuticals to Biota Pharmaceuticals Inc., a reverse stock

Prior to the merger, BioSante will distribute contingent value rights to its stockholders providing rights related to LibiGel (female testosterone gel

Protein Potential LLC, of Rockville, Md., was awarded three Phase I Small Business Innovation Research grants totaling $1.8 million from the National Institutes of Health to develop a malaria vaccine that protects against Plasmodium falciparum, the malaria parasite responsible for more than 95 percent of malaria-associated deaths worldwide...Teijin Pharma Ltd., of Tokyo, and Pulmagen Therapeutics (Asthma) Ltd., of Slough, UK, inked an exclusive licensing deal granting Teijin Japanese rights to

In other news, Ablynx said it and partner Merck Serono, a division of Darmstadt, Germany-based Merck KGgA, advanced Nanobody candidate ALX-0751 into preclinical development in cancer...In other news, Boehringer and Eli Lilly and Co., of Indianapolis, said they received a positive opinion from the European Committee for Medicinal Products for Human Use for DPP-4 inhibitor Trajenta (linagliptin) in combination with insulin in adults with Type II diabetes...are soliciting consents from note holders for

subsidiary of Tokyo-based Astellas Pharma Inc., has submitted a new drug application (NDA) to the FDA seeking approval for tacrolimus extended-release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients...It was not possible to determine if the heart failure was directly a result of Mirapex or other factors...Santaris Pharma A/S, of Hoersholm, Denmark, said the federal court in the Southern District of California granted

ImQuest BioSciences Inc., of Frederick, Md., said it received funding from the National Institutes of Health to support the development of a safe and effective microbicide product for both vaginal and rectal use...The letter is in response to opposition from one of Nabi's largest stockholders, Mangrove Partners Fund LP, which last week reached out to shareholders asking them to vote against the proposed merger, arguing that the transaction "fails to return to Nabi's stockholders the underlying